Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922018 | 0.89 | BTK (0.53) | BTKEGFRLCK | |
| SCHEMBL1921495 | 0.84 | BTK (0.53) | BTKEGFRLCK | |
| SCHEMBL9283600 | 0.83 | BTK (0.55) | BTKEGFRLCK | |
| SCHEMBL1921314 | 0.81 | BTK (0.51) | BTKEGFRLCK | |
| SCHEMBL1922320 | 0.81 | BTK (0.51) | BTKEGFRLCK | |
| SCHEMBL1921672 | 0.76 | BTK (0.47) | BTKEGFRLCK | |
| SCHEMBL1921902 | 0.76 | BTK (0.46) | BTKEGFRLCK | |
| SCHEMBL1921594 | 0.75 | BTK (0.56) | BTKEGFRLCK | |
| SCHEMBL1921675 | 0.75 | BTK (0.54) | BTKEGFRLCK | |
| SCHEMBL1921718 | 0.74 | MAPK11 (0.52) | BTKEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | claimed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | claimed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | claimed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| US-5296491-A | Pyrazolo[4,3-c]pyridines and their use as serotonin reuptake inhibitors | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-03-22 | — | — | US | claimed |
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-5428169-A | Antidepressants, treating compulsive disorders, stuttering, trichotillomania | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5380847-A | Reaction of 1-methylpiperidine-4-hydrazine, ketone and titanium isopropoxide to form hydrazone | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0594001-A1 | Pyrazolo 4,3-c pyridines, a process for their preparation and their use as serotonin reuptake inhibitors | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5296491-A | Pyrazolo[4,3-c]pyridines and their use as serotonin reuptake inhibitors | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5264576-A | Antiserotonin agents, antidepressants and obsessive-compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195992-A1 | NEW COMPOUNDS II | SSB, NFKBIA, ALOX15B | BTK 3544/4885EGFR 4867/4885LCK 1024/4885 |
| US-20140107150-A1 | New Compounds II | SSB, NFKBIA, ALOX15B | BTK 3544/4885EGFR 4867/4885LCK 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.